The breakpoint cluster region–Abelson tyrosine kinase (BCR–ABL) fusion oncoprotein drives chronic myeloid leukaemia (CML). Although therapies targeting BCR–ABL — such as the pioneering compound imatinib — have dramatically improved patient outcomes, many patients need to remain on treatment, and drug resistance can emerge. Writing in

中文翻译：

---

癌症：BCR–ABL的腰带和牙套

断点簇区域– Abelson酪氨酸激酶（BCR–ABL）融合癌蛋白驱动慢性粒细胞白血病（CML）。尽管针对BCR-ABL的疗法（例如开创性的伊马替尼等）已大大改善了患者的预后，但许多患者仍需要继续治疗，并且可能会出现耐药性。写在